SCHEDULE 13G/A: Armistice Capital and Steven Boyd Reduce Stake in Rockwell Medical to 4.99%

Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G, reporting a reduced beneficial ownership of 4.99% of Rockwell Medical, Inc.'s common stock as of March 31, 2025.

Summary

• The filing is an Amendment No. 4 to Schedule 13G for Rockwell Medical, Inc. (CUSIP: 774374300).
• The reporting persons are Armistice Capital, LLC, a Delaware entity, and Steven Boyd, a U.S. citizen.
• As of March 31, 2025, the reporting persons collectively beneficially own 3,284,144 shares of Rockwell Medical's Common Stock.
• This ownership represents 4.99% of the total class of securities.
• Both Armistice Capital, LLC and Steven Boyd have shared voting and shared dispositive power over all 3,284,144 shares.
• Armistice Capital, LLC acts as the investment manager for Armistice Capital Master Fund Ltd., which is the direct holder of the shares.
• Steven Boyd is the managing member of Armistice Capital, LLC.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 4

Explanation: Slightly negative. While a factual disclosure, the implied reduction in a significant institutional stake (from likely above 5% to 4.99%) can be perceived as a lack of continued conviction or a strategic divestment, which is generally a negative signal for the stock.

Negatives

• The reporting persons' beneficial ownership has decreased to 4.99% of Rockwell Medical's common stock. As this is an Amendment No. 4 and the current stake is just below the 5% reporting threshold, it implies a reduction from a previous position likely above 5%, which could be interpreted as a negative signal by the market.

Future Outlook

NA

Industry Context

This filing is a standard disclosure of passive ownership by an investment firm and its principal in a publicly traded company within the healthcare/pharmaceutical industry (Rockwell Medical). The reduction in stake, if confirmed, could be a point of interest for market participants assessing institutional confidence in the company.

Stakeholder Impact

• Shareholders: Provides transparency regarding significant passive ownership stakes. A reduction in stake by a notable institutional investor might lead to concerns about the company's future prospects or valuation.

Key Dates

Keywords

Rockwell Medical, Armistice Capital, Steven Boyd, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Investment Management, Passive Investment, Stake Reduction